In the current work, we hypothesized that CrkL, generally considered as a protein overexpressed intracellularly in breast cancers, when secreted from the tumor cells, can possibly also serve as a serum biomarker for breast tumors. This evidence concerns the gene CRKL and breast carcinoma.